Skip Navigation



Brain Advance Access published online on May 2, 2006

Brain, doi:10.1093/brain/awl104
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
129/7/1710    most recent
awl104v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Panzeri, C.
Right arrow Articles by Bassi, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panzeri, C.
Right arrow Articles by Bassi, M. T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received October 2, 2005
Revised February 23, 2006
Accepted March 27, 2006

Article

The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function

Chris Panzeri 1, Clara De Palma 2, Andrea Martinuzzi 3, Andrea Daga 4, Gianni De Polo 3, Nereo Bresolin 5, Christopher C. Miller 6, Elizabeth L. Tudor 6, Emilio Clementi 7, and Maria T. Bassi 1 *

1 IRCCS E. Medea, Laboratory of Molecular Biology, Bosisio Parini Lecco, Italy
2 Stem Cell Research Institute, DIBIT-H San Raffaele Scientific Institute, University of Milan, Milan, Italy; Department of Pharmaco-Biology, University of Calabria, Rende, Italy
3 IRCCS E. Medea, Conegliano Research Center, Conegliano, Italy
4 Dulbecco Telethon Institute at the Department of Pharmacology, University of Padova, Padova, Italy
5 IRCCS E. Medea, Laboratory of Molecular Biology, Bosisio Parini Lecco, Italy; Centro Dino Ferrari Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Department of Neurological Sciences, University of Milan, Milan, Italy
6 MRC Centre for Neurodegeneration Research, Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK
7 IRCCS E. Medea, Laboratory of Molecular Biology, Bosisio Parini Lecco, Italy; Stem Cell Research Institute, DIBIT-H San Raffaele Scientific Institute, University of Milan, Milan, Italy; Department of Preclinical Sciences, University of Milan, Milan, Italy

* To whom correspondence should be addressed.
Maria T. Bassi, E-mail: mariateresa.bassi{at}bp.lnf.it


   Abstract

Primary lateral sclerosis (PLS) is a rare progressive paralytic disorder that results from dysfunction of the upper motoneurons. Although PLS is a sporadic disorder of adult middle age, it has also been described in children as juvenile PLS or JPLS. The causative gene for JPLS was found to be ALS2, which is also responsible for a recessive form of amyotrophic lateral sclerosis, for infantile onset ascending hereditary spastic paralysis (IAHSP) and for a form of complicated hereditary spastic paraplegia (cHSP). ALS2 gene encodes a protein termed alsin, containing multiple guanine nucleotide exchange factor domains, specifically binding to small GTPase Rab5 and acting as a GEF for Rab5. In vitrostudies performed with full-length and truncating forms of alsin protein support its role in endosomal dynamics and trafficking of mitochondria. All ALS2 mutations so far reported generate alsin protein truncation. Here, we describe the first homozygous missense mutation in ALS2, p.G540E. The mutation, which falls within the RCC1 domain, was identified in a 34-year-old patient with typical signs of JPLS such as ascending generalized and severe spasticity involving the limbs and the bulbar region, dysphagia, limb atrophy, preserved cognition and sensation. The father and two proband's sisters were found to be heterozygous carriers of the mutation with no signs of the disease. Studies in the neuronal cell line SK-N-BE indicated that the known subcellular localization of wild-type alsin with the early endosome antigen 1, in enlarged endosomal structures, and transferrin receptor is completely lost by the mutant protein, thus indicating that this mutation leads to protein delocalization. Mutant alsin induced neuronal death itself and also significantly enhanced the apoptogenic effect of NMDA and staurosporine. This effect was associated with decreased Bcl-xL : Bax ratio. In contrast, wild-type alsin was neuroprotective and increased Bcl-xL : Bax ratio. Our results provide the first demonstration that a missense mutation in alsin is cytotoxic. In addition, the identification of Bcl-xL/Bax as target of protection by alsin and of cytotoxicity by the mutant form provides a new signalling event regulated by alsin protein that may be important to define its role in neuronal physiology and neurodegeneration. Finally, the phenotype-genotype correlation in our patient, in view of all other ALS2 mutant cases reported previously, suggests a functional interplay of long and short forms of alsin in relation to disease onset and progression.

Keywords: ALS2; alsin; missense mutation; cell death; apoptosis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
N. Ticozzi, V. Silani, A. L. LeClerc, P. Keagle, C. Gellera, A. Ratti, F. Taroni, T. J. Kwiatkowski Jr, D. M. McKenna-Yasek, P. C. Sapp, et al.
Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort
Neurology, October 13, 2009; 73(15): 1180 - 1185.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
N. Mintchev, E. Zamba-Papanicolaou, K. A. Kleopa, and K. Christodoulou
A novel ALS2 splice-site mutation in a Cypriot juvenile-onset primary lateral sclerosis family
Neurology, January 6, 2009; 72(1): 28 - 32.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
F. Gros-Louis, J. Kriz, E. Kabashi, J. McDearmid, S. Millecamps, M. Urushitani, L. Lin, P. Dion, Q. Zhu, P. Drapeau, et al.
Als2 mRNA splicing variants detected in KO mice rescue severe motor dysfunction phenotype in Als2 knock-down zebrafish
Hum. Mol. Genet., September 1, 2008; 17(17): 2691 - 2702.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H.-X. Deng, H. Zhai, R. Fu, Y. Shi, G. H. Gorrie, Y. Yang, E. Liu, M. C. Dal Canto, E. Mugnaini, and T. Siddique
Distal axonopathy in an alsin-deficient mouse model
Hum. Mol. Genet., December 1, 2007; 16(23): 2911 - 2920.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Kunita, A. Otomo, H. Mizumura, K. Suzuki-Utsunomiya, S. Hadano, and J.-E Ikeda
The Rab5 Activator ALS2/alsin Acts as a Novel Rac1 Effector through Rac1-activated Endocytosis
J. Biol. Chem., June 1, 2007; 282(22): 16599 - 16611.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. Lai, C. Xie, S. G. McCormack, H.-C. Chiang, M. K. Michalak, X. Lin, J. Chandran, H. Shim, M. Shimoji, M. R. Cookson, et al.
Amyotrophic Lateral Sclerosis 2-Deficiency Leads to Neuronal Degeneration in Amyotrophic Lateral Sclerosis through Altered AMPA Receptor Trafficking.
J. Neurosci., November 8, 2006; 26(45): 11798 - 11806.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. S. Devon, P. C. Orban, K. Gerrow, M. A. Barbieri, C. Schwab, L. P. Cao, J. R. Helm, N. Bissada, R. Cruz-Aguado, T.-L. Davidson, et al.
Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities
PNAS, June 20, 2006; 103(25): 9595 - 9600.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.